Barclays PLC reissued their equal weight rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report issued on Saturday. Barclays PLC currently has a $450.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $400.00.

Other equities analysts have also issued reports about the stock. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a buy rating in a report on Friday, May 5th. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a hold rating in a report on Monday, May 15th. Piper Jaffray Companies boosted their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an overweight rating in a report on Tuesday, June 20th. Cowen and Company restated a hold rating and issued a $380.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, May 15th. Finally, Sanford C. Bernstein restated an outperform rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. One analyst has rated the stock with a sell rating, sixteen have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $467.38.

Shares of Regeneron Pharmaceuticals (REGN) opened at 513.45 on Friday. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55. The stock has a market capitalization of $54.21 billion, a P/E ratio of 62.15 and a beta of 1.67. The company’s 50 day moving average price is $495.83 and its 200-day moving average price is $415.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same period in the previous year, the business earned $2.57 EPS. The firm’s revenue for the quarter was up 9.8% on a year-over-year basis. Equities analysts predict that Regeneron Pharmaceuticals will post $12.80 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-equal-weight-rating-reaffirmed-at-barclays-plc/1458842.html.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,000 shares of the stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the transaction, the chairman now directly owns 414,156 shares of the company’s stock, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. Insiders sold a total of 59,396 shares of company stock valued at $28,484,734 in the last ninety days. 10.40% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. BlackRock Inc. increased its position in Regeneron Pharmaceuticals by 3,331.5% in the first quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after buying an additional 5,967,733 shares during the period. Wellington Management Group LLP increased its position in Regeneron Pharmaceuticals by 7.9% in the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares during the period. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 4.1% in the first quarter. Vanguard Group Inc. now owns 5,121,496 shares of the biopharmaceutical company’s stock valued at $1,984,630,000 after buying an additional 199,975 shares during the period. State Street Corp increased its position in Regeneron Pharmaceuticals by 4.3% in the first quarter. State Street Corp now owns 3,380,151 shares of the biopharmaceutical company’s stock valued at $1,309,861,000 after buying an additional 139,602 shares during the period. Finally, Artisan Partners Limited Partnership increased its position in Regeneron Pharmaceuticals by 2.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock valued at $749,145,000 after buying an additional 41,630 shares during the period. 66.89% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.